Health outcomes of interest in observational data: Issues in identifying definitions in the literature

Health Outcomes Research in Medicine

Volumn 3, Issue 1, 2012, Pages

  Stang, Paul E ^a,b   Ryan, Patrick B ^a,b   Dusetzina, Stacie B ^c   Hartzema, Abraham G ^b,d   Reich, Christian ^b   Overhage, J Marc ^b,e   Racoosin, Judith A ^b,f  

^a JOHNSON AND JOHNSON   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

^e SIEMENS CORPORATE RESEARCH   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Claims database; Drug safety surveillance; Electronic health record database; Health outcome; Health outcome of interest; Literature search; Outcome definition; Outcomes research; Outcomes studies; Surveillance

Indexed keywords

ALGORITHM; ARTICLE; MEDICAL RESEARCH; MEDICAL SOCIETY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUBLICATION;

EID: 84861340620     PISSN: None     EISSN: 18771319     Source Type: Journal    
DOI: 10.1016/j.ehrm.2011.11.003     Document Type: Article

References (12)

1. Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf. 2001;10(5):389-392. (Pubitemid 33138459)
2. Cunnington M, Webb D, Qizilbash N, et al. Risk of ischaemic cardiovascular events from selective cyclooxygenase-2 inhibitors in osteoarthritis. Pharmacoepidemiol Drug Saf. 2008;17(6):601-608. (Pubitemid 351982766)
3. Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez- Gutthann S. Use of oral corticosteroids and the risk of acute myocardial infarction. Atherosclerosis. 2007;192(2):376-383. (Pubitemid 46745271)
4. Buehler JW, Hopkins RS, Overhage JM, Sosin DM, Tong V. Framework for evaluating public health surveillance systems for early detection of outbreaks: recommendations from the CDC Working Group. MMWR Recomm Rep. 2004;53(RR-5):1-11.
5. Proschan MA, Lan KKG, Wittes JT. Statistical Methods for Monitoring Clinical Trials. New York: Springer; 2006.
6. Solomon SD, McMurray JJ, Pfeffer MA, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(25):1071-1080. (Pubitemid 40365348)
7. Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the observational medical outcomes partnership. Ann Intern Med. 2010;153(9):600-606.
8. Department of Health and Human Services, Food and Drug Administration. 21 CFR 310 Section III D4: Safety Reporting Requirements for Human Drug and Biological Products. March 14, 2003. Available at: http://www.fda.gov/OHRMS/ DOCKETS/98fr/03-5204.pdf. Accessed November 8, 2011.
9. Lieu TA, Kulldorff M, Davis RL, et al., for the Vaccine Safety Datalink Rapid Cycle Analysis Team. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007;45(Suppl. 2): S89-S95.
10. US Food and Drug Administration. Food and Drug Administration Amendments Act of 2007, Public Law 110-85, Title IX, Section 905.
11. US Food and Drug Administration. The Sentinel Initiative: A National Strategy for Monitoring Medical Product Safety. May 2008. Available at: http://www.fda.gov/oc/initiatives/advance/reports/report0508.html. Accessed November 8, 2011.
12. US Food and Drug Administration, eHealth Foundation, and the Brookings Institute. The Sentinel Initiative: Structure, Function and Scope. Washington, DC; December 16, 2008. Available at: http://www.fda.gov/oc/initiatives/ criticalpath/transcript121608.pdf. Accessed November 8, 2011.